• Indole-3-pyruvic Acid: Pathways and Protocols

  2026-09-10

  Indole-3-pyruvic acid (IPA) is a tryptophan-derived intermediate in indole-3-acetic acid biosynthesis and a preclinical modulator of AhR, UHRF1, and AMPK-linked biology. Its reported plant, immune, arthritis, and cancer activities are context-dependent and should not be interpreted as evidence of clinical efficacy.

• KU-60019: An ATM Inhibitor for State-Aware Assays

  2026-09-10

  Explore how KU-60019, a selective ATM kinase inhibitor, can be used to dissect DNA damage response, radiosensitization, glioma invasion, and metabolism-linked vulnerabilities. This article translates ovarian cancer findings into rigorous, clearly bounded assay strategies without conflating model-specific evidence.

• Pertussis Toxin: From cAMP to TH17 Assays

  2026-09-09

  Pertussis toxin is more than a classic cAMP perturbation tool: it can help researchers separate proximal G protein signaling from downstream immune phenotypes. This article connects its use in dendritic-cell assays with new mechanistic insights into TH17 transcriptional control while defining practical limits for interpretation.

• AP20187: Chemical Inducer of Dimerization Workflows

  2026-09-09

  AP20187 enables dose-controlled fusion protein dimerization for conditional gene expression, regulated cell therapy, and metabolic signaling studies. This workflow-focused guide connects practical assay design with the senescent CAF findings in breast cancer research while clearly separating validated product uses from hypothesis-generating applications.

• Enzyme-Induced Hypoxia and NLRP3 in Urothelial Cells

  2026-09-09

  Hudson and colleagues show that hypoxia duration determines whether rat urothelial cells mount an adaptive response or activate caspase-1-associated inflammation. The work identifies a ROS/TXNIP/NLRP3-linked mechanism and provides a time-resolved framework for modeling bladder outlet obstruction-related injury in vitro.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-08

  The reference study identifies an LMO2/LDB1 protein complex as a functionally important transcriptional axis in acute myeloid leukemia (AML). Through genetic perturbation, protein interaction analysis, transcriptomics, chromatin profiling, and in vivo validation, it shows that LDB1 supports AML cell proliferation and survival, while LMO2 can partially compensate for LDB1 loss.

• NETs in CML: TKI Effects and Vascular Risk

  2026-09-07

  The reference study shows that neutrophil extracellular trap formation is elevated in treatment-naive chronic myeloid leukemia and can be differentially altered by tyrosine kinase inhibitors. Its combination of patient-derived neutrophils, pathway perturbation, and a BCR-ABL1 cellular model provides a mechanistic framework for investigating how leukemia biology and treatment-related vascular risk may intersect.

• Isradipine (Dynacirc): Reading Calcium Data

  2026-09-07

  Isradipine (Dynacirc) is an L-type calcium channel tool for connecting vascular pharmacology with neuronal calcium assays. This article explains how to use its selectivity, handling profile, and the v-Agatoxin-IVA literature to make stronger mechanistic inferences.

• ECL Western Blotting Substrate: Practical Guide

  2026-09-05

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection in Western blot assays. It is intended for HRP-linked immunoblots imaged with X-ray film or CCD systems, not for fluorescent or radioisotopic detection workflows.

• EPI-001: A Practical AR NTD Assay Strategy

  2026-09-04

  EPI-001 is an androgen receptor N-terminal domain inhibitor for dissecting ligand-dependent and ligand-independent signaling. This guide presents an assay-centered framework linking AR biology, ARv7, growth phenotypes, and metastasis-related readouts.

• 4-Phenylbutyric Acid in ER Stress Research

  2026-09-04

  Use 4-Phenylbutyric acid as a controlled chemical-chaperone intervention to test whether ER burden contributes to toxicant-induced injury. A kidney-cell workflow anchored to PFOS research combines ER-stress, ferroptosis, viability, and injury readouts to distinguish pathway rescue from nonspecific cytoprotection.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit

  2026-09-03

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit enables tunable fluorescent RNA probe synthesis for ISH and Northern blotting. This article explains how Cy3 labeling can support RNAi delivery studies while distinguishing probe visualization from functional dsRNA silencing.

• JNJ-26854165: Smarter Cancer Response Assays

  2026-09-03

  JNJ-26854165 (Serdemetan) supports more informative cancer research by separating growth inhibition from true cell killing in p53-focused models. This workflow combines HDM2 pathway modulation with orthogonal viability, apoptosis, migration, and radiation-response measurements.

• Cycloheximide: Reading Translation-Block Experiments

  2026-09-02

  Cycloheximide is a powerful protein biosynthesis inhibitor, but its value depends on interpreting translation arrest without confusing it with apoptosis. This guide connects ribosomal mechanism, protein turnover study design, caspase readouts, and disease-model limitations.

• TMRE mitochondrial membrane potential assay kit guide

  2026-09-02

  Turn ΔΨm changes into a practical readout for apoptosis, sodium-overload injury, and mitochondrial stress using TMRE with a built-in CCCP control. This workflow emphasizes plate-ready optimization, quantitative normalization, and interpretation limits across intact cells, tissue mitochondria, and purified mitochondria.

8617 records 1/575 page Next 12345 下5页 Last page